<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003258</url>
  </required_header>
  <id_info>
    <org_study_id>FAODIIPMERVO</org_study_id>
    <nct_id>NCT05003258</nct_id>
  </id_info>
  <brief_title>Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion</brief_title>
  <official_title>Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal vein occlusion (RVO) is one of the most common causes of vision loss due to retinal&#xD;
      vascular disease. Incidence of RVO has been raised in the last years due to increased&#xD;
      coexisting systemic vascular risk factors as arterial hypertension, obesity, diabetes&#xD;
      mellitus and COVID-19. Macular edema (ME) is a major sight-threatening complication of branch&#xD;
      retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). BRVO and CRVO have&#xD;
      the same pathology, an elevation in the intravascular pressure in the occluded vein leading&#xD;
      to vascular wall damage causing leakage of fluid and release of inflammatory cytokines as&#xD;
      vascular endothelial growth factor (VEGF), respectively.&#xD;
&#xD;
      In the past, the standard treatment for BRVO-related ME was grid laser photocoagulation and&#xD;
      for CRVO-related ME was observation. But subsequent randomized controlled trials demonstrated&#xD;
      significant functional and anatomical improvements among patients with ME secondary to BRVO&#xD;
      or CRVO treated with intravitreal injections of vascular endothelial growth factor (VEGF)&#xD;
      inhibitors or corticosteroids compared to those treated with laser only. Anti-VEGF therapy&#xD;
      decrease intravenous pressure, enhance blood flow and improve venous diameter and tortuosity.&#xD;
      Also, intravitreal corticosteroid injection has been shown to improve vision and central&#xD;
      macular thickness (CMT).&#xD;
&#xD;
      Dexamethasone intravitreal implant (Ozurdex®, Allergan Inc., Irvine, CA, USA) has potent&#xD;
      antiangiogenic and anti-inflammatory effects. Also it decreases the vascular permeability&#xD;
      playing an important role in treating ME secondary to RVO. However, majority of eyes have&#xD;
      been treated previously then shifted to dexamethasone implant as a second line for treatment&#xD;
      of refractory RVO related ME.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the research is To evaluate functional and anatomical outcomes of ozurdex injection in&#xD;
      patients with RVO related macular edema.&#xD;
&#xD;
      And evaluation of the safety of ozurdex injections regarding intraocular pressure increase,&#xD;
      cataract development or endophthalmitis.&#xD;
&#xD;
      Type of the study: Interventional Case Series. Study Setting: Assiut University Hospital&#xD;
      (Ophthalmology Department).&#xD;
&#xD;
      Study subjects:&#xD;
&#xD;
        1. Inclusion criteria:&#xD;
&#xD;
             1. Patients with macular edema secondary to BRVO and CRVO.&#xD;
&#xD;
             2. Presence of macular edema &gt;3oo μ on OCT evaluation.&#xD;
&#xD;
             3. visual acuity of +0.3 logarithm of the minimum angle of resolution (logMAR) or&#xD;
                worse.&#xD;
&#xD;
        2. Exclusion criteria:&#xD;
&#xD;
             1. Presence of coexisting retinal disease (such as diabetic retinopathy, age related&#xD;
                macular degeneration, vitreo-macular traction, or epiretinal membrane).&#xD;
&#xD;
             2. Media opacities (cataract) that could decrease visual acuity (VA).&#xD;
&#xD;
             3. Previous ocular trauma or vitreoretinal surgery.&#xD;
&#xD;
             4. Patients with glaucoma or known to be steroid responders.&#xD;
&#xD;
      Baseline evaluation:&#xD;
&#xD;
        1. Complete ophthalmic evaluation including assessment of distance BCVA using Snellen&#xD;
           charts and will be converted to logarithm of the minimum angle of resolution (logMAR),&#xD;
           tonometry, slit-lamp bio microscopy, gonioscopy and dilated fundus examination.&#xD;
&#xD;
        2. Thorough clinical history and review of other systems involvement as well as full drug&#xD;
           history.&#xD;
&#xD;
      Imaging:&#xD;
&#xD;
      SD-OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany) with automated CMT&#xD;
      measurements through a dilated pupil.&#xD;
&#xD;
      Color fundus photography and fluorescein angiography will be performed for every patient at&#xD;
      baseline to document the clinical appearance and type of RVO using Topcon TRC-NW8F (Topcon&#xD;
      Medical Systems, Inc., Tokyo, Japan).&#xD;
&#xD;
      OCTA will be performed before and after injection.&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      Primary (main):&#xD;
&#xD;
        -  Assessment of VA and CMT improvement after use of dexamethasone implant in macular edema&#xD;
           secondary to RVO.&#xD;
&#xD;
        -  Evaluation the safety of intravitreal Ozurdex injection regarding adverse events as IOP&#xD;
           increase, cataract development or endophthalmitis.&#xD;
&#xD;
           b. Secondary (subsidiary):&#xD;
&#xD;
        -  To evaluate the incidence and onset of occurrence of any adverse event or recurrence.&#xD;
&#xD;
        -  To correlate between BCVA and CMT throughout the duration of the study. Data collection:&#xD;
           data will recorded in the form of excel spreadsheets. Computer software: SPSS.&#xD;
           Statistical tests: Tests of normality will be performed, if data are normally&#xD;
           distributed student t-test will be done and if not, Mann-Whitney test will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>_Assessment of VA using snellen chart after use of ozurdex in macular edema secondary to RVO.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- To evaluate the incidence and onset of occurrence of any adverse event or recurrence.</measure>
    <time_frame>2 years</time_frame>
    <description>Safety of intravitreal Ozurdex injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Patients with RVO</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dexamethasone Intravitreal Implant is used in patients with Macular ar edema due to retinal vein occlusion either from the start or after unsatisfactory response to anti - VEGF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intravitreal injection of Dexamethasone implant</intervention_name>
    <description>Intravitreal injection of Dexamethasone implant</description>
    <arm_group_label>Patients with RVO</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with macular edema secondary to BRVO and CRVO.&#xD;
&#xD;
          -  Presence of macular edema &gt;3oo μ on OCT evaluation.&#xD;
&#xD;
          -  visual acuity of +0.3 logarithm of the minimum angle of resolution (logMAR) or worse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of coexisting retinal disease (such as diabetic retinopathy, age related&#xD;
             macular degeneration, vitreo-macular traction, or epiretinal membrane).&#xD;
&#xD;
          -  Media opacities (cataract) that could decrease visual acuity (VA).&#xD;
&#xD;
          -  Previous ocular trauma or vitreoretinal surgery.&#xD;
&#xD;
          -  Patients with glaucoma or known to be steroid responders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Teja S, Sawatzky L, Wiens T, Maberley D, Ma P. Ozurdex for refractory macular edema secondary to diabetes, vein occlusion, uveitis and pseudophakia. Can J Ophthalmol. 2019 Oct;54(5):540-547. doi: 10.1016/j.jcjo.2018.12.005. Epub 2019 Jan 25.</citation>
    <PMID>31564342</PMID>
  </reference>
  <reference>
    <citation>Maggio E, Mete M, Maraone G, Attanasio M, Guerriero M, Pertile G. Intravitreal Injections for Macular Edema Secondary to Retinal Vein Occlusion: Long-Term Functional and Anatomic Outcomes. J Ophthalmol. 2020 Feb 13;2020:7817542. doi: 10.1155/2020/7817542. eCollection 2020.</citation>
    <PMID>32104597</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Menatallah Gamal Saleh</investigator_full_name>
    <investigator_title>Assistant lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone Intravitreal Implant</keyword>
  <keyword>Retinal vein occlusion</keyword>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

